Solventum Corporation (NYSE:SOLV) Receives $91.64 Consensus Price Target from Analysts

Solventum Corporation (NYSE:SOLV) has been given a consensus rating of “Hold” by the thirteen analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $91.6364.

A number of equities analysts have issued reports on SOLV shares. UBS Group raised their price objective on shares of Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday. Piper Sandler upped their price target on Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Wells Fargo & Company cut their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. BTIG Research boosted their price objective on shares of Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a report on Thursday. Finally, Weiss Ratings raised shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th.

Hedge Funds Weigh In On Solventum

Several institutional investors and hedge funds have recently made changes to their positions in the company. CrossGen Wealth LLC bought a new stake in shares of Solventum in the fourth quarter worth about $25,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Solventum during the third quarter worth about $25,000. Clearstead Trust LLC lifted its holdings in shares of Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after purchasing an additional 150 shares in the last quarter. JNBA Financial Advisors lifted its holdings in shares of Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC acquired a new position in shares of Solventum in the 2nd quarter valued at approximately $28,000.

Solventum Price Performance

Shares of SOLV stock opened at $85.38 on Friday. The stock has a 50-day moving average price of $79.58 and a 200 day moving average price of $74.45. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The firm has a market cap of $14.53 billion, a price-to-earnings ratio of 10.44, a PEG ratio of 1.06 and a beta of 0.60. Solventum has a 12 month low of $62.38 and a 12 month high of $90.00.

Solventum (NYSE:SOLV) last released its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company’s revenue was up 2.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Research analysts expect that Solventum will post 7.25 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.